Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis

Abstract

Hosam Sheha,1–3 Sean Tighe,2 Omar Hashem,3 Yasutaka Hayashida4 1Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, Northwell Health, New York, NY, USA; 2Department of Ophthalmology, Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA; 3Department of Ophthalmology, Research Institute of Ophthalmology, Cairo, Egypt; 4Department of Ophthalmology, Osaka University Graduate School of Medicine, Suita, JapanCorrespondence: Hosam ShehaDepartment of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, 210 E 64th Street, New York, NY 10065, USATel [phone]Email [email protected]: Neurotrophic keratitis is an underdiagnosed degenerative condition induced by impairment to the corneal nerves which may lead to persistent epithelial defects and corneal blindness. Current medical and surgical treatments are only supportive and poorly tackle the underlying problem of corneal anesthesia; hence, fail to provide a permanent cure. Cenegermin is a newly introduced recombinant human nerve growth factor (rhNGF) that may address this issue. Preliminary clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis; however, the clinical experience with this drug is still limited. This review summarizes the pathogenesis and management of neurotrophic keratitis as well as the mechanism of action, uses, and limitations of cenegermin eye drops in the treatment of neurotrophic keratitis.Keywords: cenegermin, corneal nerves, neurotrophic keratitis, nerve growth factors, persistent epithelial defect

Keywords

• Cenegermin
• Corneal nerves
• Neurotrophic keratitis
• Nerve growth factors
• Persistent epithelial defect.